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Abstract 
Insulin autoimmune syndrome is characterised by spontaneous hypoglycaemia, and excessive 
serum insulin levels and insulin autoantibodies, which occur in the absence of exogenous 
insulin. It is seen especially with drugs containing the sulfhydryl group. Alpha lipoic acid is a 
sulfhydryl-containing antioxidant used in the treatment of diabetic neuropathy. As well as for 
diabetic neuropathy, it is frequently used in many countries for non-neuropathic pain, anti-
ageing, and diet supplementation. Although insulin autoimmune syndrome is frequently 
reported in the Asian population due to their genetic predisposition, it is rarely seen in the 
Caucasian race, as in Turkey. Herein, we report a case diagnosed with insulin autoimmune 
syndrome after alpha lipoic acid usage in combination with vitamin B due to pain. 
Key words: HLA-DR typing; hypoglycaemia; insulin autoantibodies; insulin autoimmune 
syndrome 
 
Case presentation 
Insulin autoimmune syndrome (IAS) is characterised by spontaneous hypoglycaemia, and 
excessive serum insulin levels and insulin autoantibodies, which occur in the absence of 
exogenous insulin. In particular, it is seen with drugs containing the sulfhydryl group. Alpha 
lipoic acid (ALA) is a sulfhydryl-containing antioxidant used for diabetic neuropathy, non-
neuropathic pain, and also as anti-ageing and as a dietary supplement. Although IAS is 
frequently reported in the Asian population due to its genetic predisposition, it is rarely seen in 
the Caucasian race, as in Turkey. Herein, we report a case diagnosed as IAS after using ALA 
with vitamin B due to pain. 
A 62-year-old woman referred to our clinic for experiencing hypoglycaemia episodes. Her 
complaints were over the preceding two weeks including recurrent dizziness, malaise, and 
fatigue. She had hypertension and chronic obstructive lung disease for which she was using 
telmisartan/HCT and budesonide plus formoterol. No previous diagnosis of diabetes or insulin 
administration was detected.  
At admission, informed consent form was obtained. Her body weight was 86 kg, height 155 
cm, and BMI 35.8 kg/m². Fasting plasma glucose was 59 mg/dL, C-peptide was measured as 
6.1 ng/mL, insulin > 600 uU/mL, and HbA1c 6.3%. Screening tests for primary and secondary 
adrenal insufficiency were performed; early morning cortisol and ACTH values were 18.4 and 
13.8 ug/dl, respectively. Laboratory tests at admission are listed in Table 1. She was hospitalised 
for 72 hours. In fasting test no hypoglycaemia was detected. The 72-hour fasting test result is 
shown in Figure 1.  
After detecting endogenous hyperinsulinaemia we performed MRI to exclude insulinoma. MRI 
revealed an increased size of liver by 195 mm but no mass lesion of the pancreas. Consequently, 
regarding IAS, insulin autoantibodies were measured. 
The tests showed very high insulin levels and insulin antibodies, and so IAS was diagnosed. 
She was prescribed 600 mg/daily ALA due to shoulder pain a month earlier, and her symptoms 
began at the end of the ALA treatment.  
She was advised to avoid ALA, eat small meals but frequently, eat low-carbohydrate foods, and 
avoid fasting. 
After discharge she did not experience any hypoglycaemia episodes. The insulin autoantibody 
titres and C-peptide levels during the follow-up are shown in Figure 2. 
Discussion 
We described ALA-related IAS, a rare autoimmune disorder characterised by spontaneous 
hypoglycaemia, excessive serum insulin and insulin autoantibody levels, without exposure any 
exogenous insulin [1]. 
Insulin autoimmune syndrome is common in Asian countries. It is associated with genetic 
predisposition, particularly HLA-DR4. In the Japanese population mainly DRB1*0406 and 
sometimes DRB1*0403 are prone to IAS, whereas HLADR*0403 is more common in 
Caucasians [3]. The incidence is increasing in non-Asian populations due to accelerating 
awareness and the prescription of related drugs [3]. 
In genetically predisposed individuals, the IAS is generally triggered by drugs containing 
sulphur or sulfhydryl groups such as captopril, methimazole, imipenem, propylthiouracil, and 
d-penicillamine. ALA, also containing a sulfhydryl group, was first reported to induce IAS in 
Japan and was subsequently noticed in many other countries [4, 5].  
IAS is extremely rare in Caucasians. Gullo et al. analysed six ALA-associated IAS, with HLA-
DRB1*04:03 allele in five and HLA-DRB1*04:06 only in one [5]. In Europe, the low incidence 
of IAS may be related with the low prevalence of HLA-DRB1*04:06.   
The sulfhydryl group-containing drugs may induce insulin autoantibody production [1]. These 
endogenous antibodies bind to insulin and proinsulin receptors and cause prolonged pancreatic 
insulin and C-peptide secretion. Insulin and C-peptide secretions continue until the binding 
capacity of circulating insulin antibodies passes over. Active free insulin increases and lowers 
blood glucose to hypoglycaemia levels [5]. 
Certain HLA groups are associated with IAS. Although, HLA-DRB1*0406 is more frequent in 
Japanese, IAS in Europe shows a correlation with DRB1*04:03 allele that has a high prevalence 
in Caucasians [5]. In our patient, HLA- DRB1*04:03 and ALA exposure played a role in the 
development of IAS.  
Clinical symptoms of IAS vary from mild cases to severe hypoglycaemia. In contrast to 
insulinoma that is presented mostly with adrenergic symptoms, IAS usually causes postprandial 
hypoglycaemia associated with neuroglycopaenic symptoms. Also, insulinoma is accompanied 
by much lower insulin levels than IAS whereas C-peptide levels are almost equivalent [1].  
In most cases, discontinuation of the drug reduces the hypoglycaemia episodes, even though 
the total remission time may last for three months.  
Because ALA consumption is increasing worldwide, clinicians should be aware of the potential 
interactions the drug can cause. Among patients using sulfhydryl-containing drugs and 
presenting with hypoglycaemia and extremely high levels of insulin, IAS should be considered 
rather than insulinoma. 
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Table I. Result of the laboratory test at admission  
Parameters   Reference range  
WBC [10³/uL] 5.11 4–10  
Hgb [g/dl] 11.2 11–15 
HCT (%) 34.2 36–47 
PLT [10³/uL] 233 100–400 
Glucose [mg/dl] 59 < 70 mg hypoglycaemia 
C-peptide [ng/mL] 6.1 0.90–7.1  
Insulin [uU/ml] > 600 1.9–23  
 
Figure 1. 72-hour fasting plasma glucose levels 
  
Figure 2. Insulin and insulin autoantibody titres during the follow-up 
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